Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com  x.com 

Aehr Test Systems' AI wafer-level burn-in business is scaling, with a $22M follow-on order from its lead AI processor customer to expand capacity for high-volume production. That customer is already planning more capacity, and Aehr is expanding talks with other hyperscalers. The stock reached fresh all-time highs, and its recent strength looks like institutional accumulation. x.com  x.com  x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr Test Systems stands to benefit from Broadcom's custom AI chip ramp because these 600W–2kW multi-die packages need burn-in testing. Broadcom said XPU shipments rose 3.5x and laid out $115B of AI revenue in FY27 and $230B in FY28 with supply secured, backed by multi-gigawatt Google, Anthropic, OpenAI and Meta deployments. Aehr won a record $41M package-level burn-in order from its lead hyperscale customer for a custom AI ASIC, with a next-gen device moving to production later this year. x.com 

Aehr Test Systems has become a key picks-and-shovels supplier to the AI chip boom, with its Sonoma platform the go-to system for reliability testing of high-power AI processors. On April 16, 2026, it announced a $41M follow-on order, its largest ever, from an unnamed hyperscale AI chip leader for custom AI ASIC testing, with revenue from fiscal 2027. Backlog doubled to $38.7M, second-half FY26 bookings exceed $92M, and FY26 should hit the high end of $45-50M guidance. x.com 

Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com  x.com 

Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Aehr Test Systems had a great quarterly call, and the stock now sits at a key pivot. x.com 

Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.com 

Aehr Test Systems is growing fast across several verticals, with its lead AI processor customer placing another $22M follow-on order for wafer-level burn-in systems. The tiny company is expanding into memory and silicon photonics as well, and at about $1.1B market cap it looks extremely promising, resembling an early Teradyne. x.com